However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard ...

MoonLake's shares rose 19% in extended trading. Merck submitted a nonbinding offer for MoonLake earlier this year, according ...

U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

Merck’s investigational KRAS G12C inhibitor, MK-1084 shows antitumor activity in phase 1 trial of patients with advanced CRC and NSCLC whose tumours harbour KRAS G12C mutations Rahway, New Jersey ...

Bristol Myers Squibb leapt into the drug industry’s most intense new rivalry on Monday, signing a deal to potentially spend ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...